While accumulating evidence indicates the potential of ANGPTL8 as a novel biomarker and/or therapeutic target for a myriad of metabolic disorders, there have been conflicting results showing a bidirectional correlation of circulating ANGPTL8 levels with NAFLD, obesity, type 2 diabetes, and dyslipidemia [15,44,152,153,154,155,156], which altogether, warrant a further comprehensive investigation. The gene discussed is ANGPTL8; the disease is metabolic dysfunction-associated steatotic liver disease.